


## CURRICULUM VITAE



**Name: Professor Michael Firer**

**Email: firer@ariel.ac.il**

**Phone: +97239066212 or +972543394865**

**Fax: +97239066323**

**Position: Principal Investigator, Dept. Chemical Engineering & Biotechnology,  
Deputy Dean, Adelson School of Medicine,  
Director, Ariel Center of Applied Cancer Research**

**Institution:** Ariel University

**Location:** Ariel, Israel

**Education:** BSc(Hons), Monash University, Victoria, Australia; Ph.D, Melbourne University, Victoria, Australia; Post-doc, Weizmann Institute of Science, Rehovot, Israel

**Representative Careers:** R&D Manager, BioHytech, Israel; Head of Biotechnology, College of Judea & Samaria, Israel; Chairman, Department of Chemical Engineering, Ariel University, Israel

**Specialty & Present Interest:** Immunology, Targeted Drug Delivery; Precision cellular immunotherapy

### **Representative papers (up to 5):**

1. **Firer, M.A.**, Laptev, R., Kasatkin, I. & Trombka, D. (2003). Specific destruction of hybridoma cells by antigen-toxin conjugates demonstrate an efficient strategy for targeted drug therapy in leukemias of the B cell lineage. *Leukemia and Lymphoma* 44; 681-689.
2. **Firer, MA.** & Gellerman, G (2012). Targeted drug delivery for cancer therapy: the other side of antibodies. *J. Hematol. Oncol.* 5:70 (1-16).doi:10.1186/1756-8722-5-70;
3. Gilad y., **Firer MA.** & Gellerman G. (2016). Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells. *Biomedicines*, 4, 11-25.
4. Bashari O, Redko B, Luboshits G, Gellerman G and **Firer MA.** (2017). Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells. *Cancer Letters* 408: 164-173.
5. Yado, S., Luboshits, G., Or, R. and Firer MA. A new adoptive cellular immunotherapy for the treatment of multiple myeloma without development of graft-versus-host disease (*under review*).